Evotec And Bayer Kidney Disease Collaboration Advances SEMA3A Monoclonal Antibody Program Into Phase 2 Clinical Development

Benzinga · 2d ago
  • Phase 2 clinical trial initiated to evaluate SEMA3A mAb as potential treatment for Alport syndrome
  • Milestone payment to Evotec expected upon first dosing of first study participant in early 2026